论文部分内容阅读
目的观察阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的疗效。方法将98例慢性乙型肝炎肝纤维化患者随机分为两组,各49例。阿德福韦酯联合复方鳖甲软肝片为治疗组,单用阿德福韦酯为对照组,疗程为1年。观察比较两组患者肝功能、HBV-DNA、HBeAg及肝纤维化指标的变化。结果治疗组的肝功复常率、HBeAg及HBV-DNA阴转率、肝纤维化程度改善均明显高于对照组(P<0.05)。结论阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化疗效显著,值得临床推广应用。
Objective To observe the curative effect of adefovir dipivoxil and Fufang Biejia Ruangan Tablet in treating chronic hepatitis B liver fibrosis. Methods 98 patients with chronic hepatitis B liver fibrosis were randomly divided into two groups, 49 cases each. Adefovir dipivoxil combined with Fufang Biejia Ruangan Tablet for the treatment group, adefovir dipivoxil alone for the control group, the course of treatment for 1 year. The changes of liver function, HBV-DNA, HBeAg and liver fibrosis in two groups were observed and compared. Results The liver function recovery rate, HBeAg and HBV-DNA negative conversion rate and the degree of hepatic fibrosis in the treatment group were significantly higher than those in the control group (P <0.05). Conclusion Adefovir dipivoxil and Fufang Biejia Ruangan Tablet have a significant therapeutic effect on chronic hepatitis B liver fibrosis, which is worthy of clinical application.